Department of Defense Peer Reviewed Cancer Research Program Funding Opportunity
for Fiscal Year 2011
Discovery Award Pre-Announcement
Fiscal Year 2011 (FY11) Defense Appropriation Act provides for $ 16 million (M) to the Department of Defense (DOD) Peer Reviewed Cancer Research Program (PRCRP) to research cancers not addressed in breast, prostate, lung (excluding Mesothelioma), and ovarian cancer research programs currently executed by the DOD U.S. Army Medical Research and Materiel Command (USAMRMC). The funds provided are directed to be used to conduct research for the following topic areas:
*Genetic Cancer Research
*Listeria Vaccine for Cancer
*Melanoma and Other Skin Cancers
*Radiation Protection Utilizing Nanotechnology
This program is administrated by the USAMRMC through the Office of the Congressionally Directed Medical Research Programs (CDMRP).
Information in this pre-announcement is being provided to allow investigators time to plan and develop applications. All proposals must confirm to the final Program Announcement and General Application Instructions (including deadlines) that will be available for electronic downloading from the Grants.gov website in late August or early September 2011. The application package containing the required forms for each award mechanism will also be found on Grants.gov.
A pre-application is required and must be submitted through the CDMRP eReceipt website (https://cdmrp.org) prior to proposal submission. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Requests for email notification of the release of the program announcements may be sent to email@example.com. For more information about the PRCRP or other CDMRP programs, please visit the CDMRP website (http://cdmrp.army.mil).
Discovery Award maximum funding $ 200,000 in direct costs--
*Supports the exploration of highly innovative, untested, high risk/potentially high reward concepts, theories, paradigms and/or methods to address one or more of the FY11 PRCRP Topic Areas
*Applications must not address breast, prostate, lung (excluding Mesothelioma), or ovarian cancer research
*Preliminary data is strongly discouraged
*Clinical trials will not be supported
Point of Contact:
CDMRP Public Affairs